Background

White hat bias was first described in obesity research, where evidence presentation sometimes appeared to favour conclusions deemed socially desirable or morally justified. Similar tendencies have since been noted across public-health research, where strong moral or societal motivations frequently accompany scientific inquiry.

The bias can influence multiple stages of the research lifecycle, including hypothesis formulation, study design, analysis, interpretation, peer review, and dissemination. It may be more pronounced in non-randomised or observational studies, where enhanced analytic flexibility can lead to greater potential for selective interpretation.

Detection is difficult because unbalanced interpretations are often framed as promoting beneficial health outcomes or preventing harm. This may occur inadvertently when researchers align interpretation with underlying value commitments rather than through deliberate distortion.

Manifestations of white hat bias include selective citation of supportive studies, omission of less favourable results, over- or underestimation of effect sizes, selective emphasis or dismissal of particular findings, variable standards for judging study quality and result significance, and inconsistent evidential criteria depending on whether results align with a favoured narrative. 

Bias may result from a range of similar but distinct influencing factors, including financial, ideological, and academic, which may overlap with white hat bias. Scrutiny should therefore be applied consistently to all potential influences on the interpretation of evidence.

Potential consequences include distorted interpretation of evidence, inappropriate influence on clinical practice or public-health messaging, and policy decisions informed by incomplete or selectively presented findings. Such effects may obscure knowledge gaps, influence research priorities, and, over time, undermine trust in advocacy and scientific research.

Example

An analysis of longitudinal data reported that vaping increased the risk of heart attacks. A subsequent critique showed that many heart attacks in the dataset occurred years before participants started vaping, meaning the study had misclassified the temporal order of exposure and outcome. Despite this, the published abstract and associated communications framed vaping as a causal risk factor. This selective framing and overstatement of harm, despite the underlying temporal inconsistency, are consistent with mechanisms of white hat bias, particularly in research areas where behaviours are widely perceived as detrimental to public health. The paper was later retracted.

In autism research, white hat bias manifests through the selective prioritisation of research efforts on underlying pathology, screening, and diagnosis (including the testing of embryos) over the development and evaluation of effective interventions to support people with autism. This disproportionately favours a narrative that characterises the neurodevelopmental differences linked to autism as falling outside natural human variation and therefore a target of elimination or cure. This occurs to the detriment of intervention-focused research based on the perspective that neurodevelopmental differences, particularly those associated with milder expressions of autism, constitute part of the natural variation in human cognition and should therefore be accommodated and valued.

Impact

An analysis of 437 articles citing the ACTT-1 trial of remdesivir (an antiviral agent) for COVID-19 showed asymmetry in how the trial’s findings were represented in the subsequent literature, with 55.8% of citing articles reporting only beneficial outcomes, and 6.4% reporting only harms.

This pattern of selective emphasis of certain findings while downplaying or excluding others reflects mechanisms consistent with white hat bias. Evidence aligned with a perceived socially urgent or desirable narrative, in this case, the hope for effective treatments during the pandemic, was preferentially highlighted. This form of selective reporting can distort the apparent balance of evidence, amplify preferred findings, and affect how clinicians and the public perceive the strength and direction of research outcomes. Although the pattern aligns with features of white hat bias, co-occurring factors such as optimism bias or editorial prioritisation during the pandemic may also have contributed. This underscores the critical need to consider moral or societal motivations as potential drivers of bias in scientific reporting.

Preventive steps

White hat bias is the result of individuals’ values and beliefs, making it difficult to recognise internally. Mitigating white hat bias requires systematic and transparent research practices, and the independent evaluation of evidence. 

Well-conducted systematic reviews should inform decision-making wherever possible. Research findings should be interpreted within established evidence hierarchies, with exceptions only when there is specific need. Causal claims and statements of policy implications should be proportionate to the underlying study designs and quality of evidence relative to established methods of evidence-based healthcare. This should be done both in primary research and in citations of research findings.

Researchers should provide clear declarations of financial and non-financial interests, including advocacy positions or other commitments that may influence study framing or interpretation. Where appropriate, reflexivity statements may make explicit how researchers’ assumptions or perspectives may shape choices about outcomes, interpretation, or communication.

Pre-registration of protocols and analysis plans, together with rigorous peer-review of methods, reduces opportunities for selective reporting or post-hoc analytical choices. Independent replication, re-analysis, and methodological scrutiny can be instrumental in detecting inflated or unbalanced claims.